This group further investigated the role of SORL1 in mediating targeted therapy resistance in breast cancer and discovered that SORL1 is necessary for HER2-HER3-driven oncogenic cell growth (Al-Akhrass et al., 2021). Here, ERBB2 is linked to breast cancer.